
Heli Malm

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/472169/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Second-generation antipsychotic use during pregnancy and risk of congenital malformations. European Journal of Clinical Pharmacology, 2021, 77, 1737-1745.	1.9	16
2	Second-generation antipsychotics and pregnancy complications. European Journal of Clinical Pharmacology, 2020, 76, 107-115.	1.9	22
3	Placental transporterâ€mediated drug interactions and offspring congenital anomalies. British Journal of Clinical Pharmacology, 2020, 86, 868-879.	2.4	9
4	Diagnosis and management of individuals with Fetal Valproate Spectrum Disorder; a consensus statement from the European Reference Network for Congenital Malformations and Intellectual Disability. Orphanet Journal of Rare Diseases, 2019, 14, 180.	2.7	33
5	Serotonin Reuptake Inhibitor Use During Pregnancy—Reply. JAMA Psychiatry, 2017, 74, 539.	11.0	0
6	New Insights into How Serotonin Selective Reuptake Inhibitors Shape the Developing Brain. Birth Defects Research, 2017, 109, 924-932.	1.5	47
7	Dr. Malm etÂal. reply:. Journal of the American Academy of Child and Adolescent Psychiatry, 2016, 55, 726-727.	0.5	0
8	Association of Selective Serotonin Reuptake Inhibitor Exposure During Pregnancy With Speech, Scholastic, and Motor Disorders in Offspring. JAMA Psychiatry, 2016, 73, 1163.	11.0	117
9	Gestational Exposure to Selective Serotonin Reuptake Inhibitors and Offspring Psychiatric Disorders: A National Register-Based Study. Journal of the American Academy of Child and Adolescent Psychiatry, 2016, 55, 359-366.	0.5	170
10	Pregnancy Outcome Following Maternal Exposure to Mirtazapine. Journal of Clinical Psychopharmacology, 2015, 35, 250-259.	1.4	32
11	Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design. BMJ, The, 2015, 350, h1798-h1798.	6.0	152
12	Genetic variants within the serotonin transporter associated with familial risk for major depression. Psychiatry Research, 2015, 228, 170-173.	3.3	13
13	Early pregnancy cerebral venous thrombosis and status epilepticus treated with levetiracetam and lacosamide throughout pregnancy. Reproductive Toxicology, 2015, 57, 204-206.	2.9	25
14	Pregnancy outcome after TNFâ€Î± inhibitor therapy during the first trimester: a prospective multicentre cohort study. British Journal of Clinical Pharmacology, 2015, 80, 727-739.	2.4	125
15	Pregnancy Complications Following Prenatal Exposure to SSRIs or Maternal Psychiatric Disorders: Results From Population-Based National Register Data. American Journal of Psychiatry, 2015, 172, 1224-1232.	7.2	106
16	Specialized Service Use for Psychiatric and Neurodevelopmental Disorders by Age 14 in Finland. Psychiatric Services, 2014, 65, 367-373.	2.0	26
17	Effects of Maternal Epilepsy and Antiepileptic Drug Use during Pregnancy on Perinatal Health in Offspring: Nationwide, Retrospective Cohort Study in Finland. Drug Safety, 2013, 36, 359-369.	3.2	52
18	Prenatal Exposure to Selective Serotonin Reuptake Inhibitors and Infant Outcome. Therapeutic Drug Monitoring, 2012, 34, 607-614.	2.0	23

Heli Malm

#	Article	IF	CITATIONS
19	Infant and childhood neurodevelopmental outcomes following prenatal exposure to selective serotonin reuptake inhibitors: overview and design of a Finnish Register-Based Study (FinESSI). BMC Psychiatry, 2012, 12, 217.	2.6	19
20	Selective Serotonin Reuptake Inhibitors and Risk for Major Congenital Anomalies. Obstetrics and Gynecology, 2011, 118, 111-120.	2.4	183
21	Selective Serotonin Reuptake Inhibitors and Risk for Major Congenital Anomalies. Obstetrics and Gynecology, 2011, 118, 1420-1421.	2.4	1
22	Nationwide registerâ€based surveillance system on drugs and pregnancy in Finland 1996–2006. Pharmacoepidemiology and Drug Safety, 2011, 20, 729-738.	1.9	39
23	Risks associated with in utero and lactation exposure to selective serotonin reuptake inhibitors (SSRIs). Reproductive Toxicology, 2010, 30, 249-260.	2.9	71
24	Evaluation of the Risk of Congenital Cardiovascular Defects Associated With Use of Paroxetine During Pregnancy. American Journal of Psychiatry, 2008, 165, 749-752.	7.2	164
25	Paroxetine and congenital malformations: Meta-Analysis and consideration of potential confounding factors. Clinical Therapeutics, 2007, 29, 918-926.	2.5	214
26	Risks Associated With Selective Serotonin Reuptake Inhibitors in Pregnancy. Obstetrics and Gynecology, 2005, 106, 1289-1296.	2.4	180
27	Prescription of Hazardous Drugs During Pregnancy. Drug Safety, 2004, 27, 899-908.	3.2	50
28	Prescription drugs during pregnancy and lactation—a Finnish register-based study. European Journal of Clinical Pharmacology, 2003, 59, 127-133.	1.9	74